banner_RIS
Can't find it?
Dr. Louis Fenkell
Dr. Louis Fenkell
Radiation Oncologist
Stronach Regional Health Centre
905-895-4521 Ext. 6595

Education:

Bachelor of Science, Doctor of Medicine, University of Toronto Resident; Department of General Surgery, University of Toronto Resident; Department of Radiation Oncology.

Associations and Affiliations:

The College of Physicians and Surgeons of Ontario, Canadian Association of Radiation Oncologists, and the American Society for Radiation Oncology.

Research Focus:

Dr. Fenkell main's research focus is on Genitourinary and breast malignancies.

Research Summary of Key Projects:

Title: A Randomized Trial of a Shorter Radiation Fractionation Schedule for the Treatment of Localized Prostate Cancer (PROFIT).

Purpose: This trial is designed to determine whether an 8-week course of escalated dose conformal radiation can be compressed safely, and with similar efficacy into a 4-week course.

For more information: http://http://clinicaltrials.gov/ct2/show/NCT00304759

In April 2011, the Radiation Medicine Program at Southlake implemented Volumetric Modulated Arc Therapy (VMAT) in the treatment of patients with prostate cancer. The Stronach Cancer Centre was the first centre across the Central LHIN to utilize VMAT in the treatment of prostate cancer. Major benefits of VMAT include significantly faster and potentially more comfortable treatment.

Research Goals:

With over 1,200 patients participating internationally, the PROFIT research trial hopes to lead to a significant reduction in the duration of prostate cancer treatment and considerable benefits to patients, their families and the community.

Future Goals and Interest in Research:

Dr. Fenkell is interested in investigating novel techniques and technologies in the treatment of prostate cancer that allow for better cancer targeting and decreased side effects.

Related Articles and Publications:

Plasma urokinase antigen and plasminogen activator inhibitor-1 antigen levels predict angiographic coronary restenosis.

Arterial repair after stenting and the effects of gm6001, a matrix metalloproteinase inhibitor

Microarray-based identification of differentially expressed growth- and metastasis-associated genes in pancreatic cancer.

Dosimetric comparison of IMRT vs. 3D conformal radiotherapy in the treatment of cancer of the cervical esophagus.

Parametrial boost using midline shielding results in an unpredictable dose to tumor and organs at risk in combined external beam radiotherapy and brachytherapy for locally advanced cervical cancer.

Evaluation of variability in seroma delineation between clinical specialist radiation therapist and radiation oncologist for adjuvant breast irradiation

 

Southlake Regional Health Centre
596 Davis Drive, Newmarket, Ontario   L3Y 2P9
Tel: 905-895-4521   |   TTY: 905-952-3062
Copyright © 2012 Southlake Regional Health Centre
rss